Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.
about
TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implicationsOxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteinsEvolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Hepatocyte death: a clear and present danger.Hepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathwayPotent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.HIV infection increases HCV-induced hepatocyte apoptosis.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Foxp3 expression in liver correlates with the degree but not the cause of inflammation.Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis.Coinfection with HIV-1 and HCV--a one-two punch.The TRAIL to viral pathogenesis: the good, the bad and the uglyThirteen-week Intravenous Toxicity Study of a Novel Humanized Anti-Human Death Receptor 5 Monoclonal Antibody, CS-1008, in Cynomolgus Monkeys.Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.Cellular and molecular mechanisms of liver injury.TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouseSystemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.Midkine secretion protects Hep3B cells from cadmium induced cellular damage.Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal ToxicityMolecular mechanisms of lipotoxicity in nonalcoholic fatty liver diseaseDeath receptors as targets for anti-cancer therapy.Cell death pathways--potential therapeutic targets.Caspase inhibitors for the treatment of hepatitis C.Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndromeTRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?Mechanisms of cell death in acute liver failure.Systemic tumor-specific gene delivery.Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.Engineering Stem Cells for Biomedical Applications.Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.Targeting cell death signalling in cancer: minimising 'Collateral damage'.Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes.CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway.
P2860
Q28539681-814D29F6-D3F0-4825-92A5-83D889067A39Q33485621-22DA6ACC-88E7-4F02-B033-A0D3C5CB6530Q33755829-665AE97C-259D-43B4-ADBA-7D7C55B26EACQ34147508-33131AED-EA86-4807-9FA0-E57C7B0F0FE9Q34291165-B964EAF2-4D51-4D09-9A0D-72F5D439544AQ34546374-FABDEF88-03F1-4A2C-9D2E-22D9B1B09450Q34699457-53DEC5FE-953C-466C-A511-0F9F9EBA9B35Q35038107-FF8513E2-65D6-4CA7-83E3-B8E1253A05D2Q35104601-4099215E-4361-489A-BA7A-59C4B60EFBC1Q35122049-35E4E981-A1EE-4878-AEAF-CA48E771FB2CQ35137038-8573D15F-A821-4943-86C7-7634859C2F68Q35146349-A05429DF-8F99-4C1E-A618-184A94CB73A3Q35603999-270BE34A-2D86-4D69-BFF5-86318EBC8893Q36327671-35DDA1B1-C704-442B-A743-4F6E2C6BF9E8Q36471345-7F3D8D12-AD1C-4646-83D6-C139D372A26CQ36777316-4B8762E2-0A16-441C-A30F-FC5ECF29A9A3Q36825315-EC2D302F-9818-4BBF-A626-B1D6543B7C52Q36908855-E02EEA40-2D64-4583-A0F7-A0C4BDF15A48Q36943407-3FB291D7-E75A-4758-9E53-0536A962EF8EQ37028654-2F8CD692-0B4D-4FB9-A416-8249950371A5Q37169731-1B124CE1-EF32-4FE7-A249-BAB1B0D86455Q37185605-2A8EF565-68A7-4A96-A8B8-938CA86A620FQ37189403-BC513445-C6BE-4B99-9752-65170F20BC0EQ37211515-125D6872-7F6F-40F6-903E-17FF6B583EEAQ37310283-C2288F80-5A05-47C7-A8C0-336D5114C7EAQ37390893-3A6A5631-0498-4485-8B66-4A12985455E5Q37557634-6B54BA9F-833A-4550-A620-B539515A2A25Q37560275-3B414052-80FD-4891-8383-337D018B6AC5Q37577467-702A1455-54AD-4664-8E70-C1B4DF6BFE4CQ37785559-1B5CC1CC-F9B6-4AFB-A905-2B90CFA0C101Q37799251-FA373D7A-29EC-4270-BA68-3C3C096E498FQ37863134-18E95697-22B1-4153-A9E2-F3DA1A737C52Q38000987-C839B609-7E6E-4A8F-BBCE-0837399AE7CBQ38137609-9688F500-7FEB-4A4C-9033-64CCF81BE236Q38168505-778B9193-1C4C-41C1-AFA1-035EC6D42D3CQ38378499-AD1422C3-C5E1-474B-9549-4A132E8AB4D9Q38799232-D1DFFA97-166A-45FC-81C0-A35A14170614Q38824157-BC4B442D-6205-4CBC-A47C-F167F29349C3Q38892529-F4F9653F-A562-42C7-892B-D0EEBE429D1AQ39311520-CF20E93F-21CA-4FA9-8C83-6482BBBF3E0B
P2860
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@en
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@nl
type
label
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@en
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@nl
prefLabel
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@en
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@nl
P2093
P356
P1433
P1476
Increased hepatotoxicity of tu ...... igand in diseased human liver.
@en
P2093
Frank Lehner
Gerald M Cohen
Heike Bantel
Klaus Schulze-Osthoff
Marion Macfarlane
Matthias J Bahr
Michael Ott
Michael P Manns
Ute Fischer
Xandra Volkmann
P304
P356
10.1002/HEP.21846
P407
P577
2007-11-01T00:00:00Z